KINDERÄRZTE.SCHWEIZ 3/2020

32 FORTB I LDUNG: THEMENHEFTTE I L 03 / 2020 K I N D E R Ä R Z T E . SCHWEIZ REFERENZEN 1. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25. 2. Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8:108–352. 3. Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. Euro- pean Academy of Allergy and Clinical Immunology (EAACI), 2015. Available at: http://www.eaaci.org/globalatlas/ENT_Atlas_web.pdf. Accessed February 15, 2018. 4. Canonica GW, Bachert C, Hellings P, et al. Allergen Immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J. 2015;8:31. 5. Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11:1321– 1333. 6. Jutel M, Agache I, Bonini S, et al. International consensus on aller- gy immunotherapy. J Allergy Clin Immunol. 2015;136:556–568. 7. Reithofer M, Boll SL, Kitzmuller C, et al. Alum-adjuvanted aller- goids induce functional IgE-blocking antibodies. Clin Exp Allergy. 2018;48:741–744. 8. Wahn U, Bachert C, Heinrich J, Richter, H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2018;00:1–11. https://doi. org/10.1111/all.13598. 9. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environ- mental Medicine (GPA), the Medical Association of German Aller- gologists (AeDA), the Austrian Society for Allergy and Immunolo- gy (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respira- tory Society (DGP), the German Association of ENT Surgeons (BV– HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319. 10. Schmid-Grendelmeier P. Rekombinante Allergene. Routinediagnos- tik oder Wissenschaft? Hautarzt 2010;61:946–53. 11. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), eds. Nationale Versorgungs Leitlinie Asthma. 12. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with season- al rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251–6. Niggemann B, Jacobsen L, Dreborg S et al. Five- year follow-up on the PAT study: specific immunotherapy and long- term prevention of asthma in children. Allergy 2006;61:855–9. 14. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunothera- py has long-term preventive effect of seasonal and perennial asth- ma: 10-year follow-up on the PAT study. Allergy 2007;62:943–8 15. Birk AO, Andersen JS, Villesen HH, Steffensen MA, Calderon MA. Tol- erability of the SQ Tree SLIT tablet in adults. Clin Ther. 2017;39:1858– 1867. https://doi.org/10.1016/j.clinthera.2017.08.003. 16. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of, preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306–12. 17. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year fol- low-up after discontinuation of preseasonal grass pollen immuno- therapy in childhood. Allergy 2006;61:198–201. 18. Purello-D‘Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to spe- cific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31: 1295–302. 19. Pajno GB, Barberio G, De Luca F, Morabito L, and Parmiani, S. Prevention of new sensitizations in asthmatic children monosensi- tized to house dust mite by specific immunotherapy. A six-year fol- low-up study. Clin Exp Allergy 2001;31:1392–7. 20. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sub- lingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206–10. 21. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua, G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969–75. 22. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E, et al. Standards for practical allergen-specific im- munotherapy. Allergy. 2006;61 Suppl 82:1–20. 23. Kelso JM. The rate of systemic reactions to immunotherapy injec- tions is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004 Feb;92(2):225–7. 24. Frost L, Johansen P, Pedersen S, Veien N, Ostergaard PA, Niels- en MH. Persistent subcutaneous nodules in children hyposensi- tized with aluminium-containing allergen extracts. Allergy. 1985 Jul;40(5):368–72. 25. Vogelbruch M, Nuss B, Korner M, Kapp A, Kiehl P, Bohm W. Al- uminium-induced granulomas after inaccurate intradermal hypo- sensitization injections of aluminium-adsorbed depot preparations. Allergy. 2000 Sep;55(9):883–7. 26. Netterlid E, Hindsen M, Bjork J, Ekqvist S, Guner N, Henricson KA, et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hypo- sensitization therapy. Contact Dermatitis. 2009 Jan;60(1):41–9. 27. Ragusa FV, Passalacqua G, Gambardella R, Campanari S, Barbieri MM, Scordamaglia A, et al. Nonfatal systemic reactions to subcu- taneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol. 1997 May-Jun;7(3):151–4. 28. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Com- mittee AAoAA, Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004 Jun;113(6):1129–36. 29. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol. 2013 Apr;110(4):274–8, 78 e1. 30. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultra- rush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000 May;55(5):484–8. 31. Calabria CW, Cox L. Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin North Am. 2011 May;31(2):251–63, ix. 32. Calabria CW. Accelerated immunotherapy schedules. Curr Allergy Asthma Rep. 2013 Aug;13(4):389–98.